Olr747 inhibitors are a specialized class of chemical compounds that function by specifically targeting and inhibiting the activity of the Olr747 receptor. This receptor is part of a larger family of G-protein coupled receptors (GPCRs) that are critical in various cellular signaling pathways. The inhibition of Olr747 typically involves binding to the active site of the receptor, thereby preventing the normal ligand from initiating its signal transduction cascade. The structural complexity of these inhibitors often includes a core scaffold that interacts with key amino acids in the receptor's binding pocket, stabilizing the inactive conformation of Olr747. This stabilization is crucial for effectively halting the downstream signaling processes that would normally be triggered by the receptor's activation.
The design and synthesis of Olr747 inhibitors require an in-depth understanding of the receptor's structure, often derived from advanced techniques such as X-ray crystallography or cryo-electron microscopy. Researchers utilize this structural information to identify potential binding sites and to guide the rational design of molecules with high affinity and specificity for Olr747. Additionally, computational methods such as molecular docking and dynamics simulations are employed to predict the binding interactions and optimize the inhibitor molecules. The development of Olr747 inhibitors also involves extensive chemical modifications and optimizations to enhance their stability, solubility, and overall efficacy as receptor antagonists. By meticulously fine-tuning these properties, researchers can create inhibitors that are not only potent but also possess desirable pharmacokinetic characteristics for further research and study.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, might modulate GPCR activity affecting Olr747. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, could influence Olr747 signaling. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, may affect GPCR signaling pathways related to Olr747. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Combined alpha and beta blocker, could indirectly affect GPCR pathways including Olr747. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr747. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist, could indirectly affect Olr747 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr747. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr747. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr747. | ||||||